Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Quetiapine 25 mg in Healthy Adults
NCT05235230Phase 1Completed
- Sponsor
- Future University in Egypt
- Start
- May 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of quetiapine in schizophrenia and bipolar disorder (BD) (2 arms), sponsored by Future University in Egypt. Primary endpoints: Maximum plasma concentration, Area under the plasma concentration curve from administration to last observed concentration and 1 more. Started May 2021; status: completed.
02
Drugs
quetiapine
03
Conditions
schizophreniabipolar disorder (BD)
Beyond the preview
Go deeper on NCT05235230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05235230.